Manhattan Institute for Policy Research.
Subscribe   Subscribe   MI on Facebook Find us on Twitter Find us on Instagram      

If you have reached this site in search of recent news events and a video surrounding Planned Parenthood, you have reached the incorrect website and organization. We are the Center for Medical Progress at the Manhattan Institute which is different than the individual organization, Center for Medical Progress.

The Center for Medical Progress is dedicated to articulating the importance of medical progress and the connection between free-market institutions and making medical progress both possible and widely available throughout the world. We encourage the development of market-based policy alternatives to sustain medical progress and promote medical innovation.

The Center for Medical Progress produces a variety of publications and hosts regular forums on issues of concern to medical progress and health care policy. For more information, please contact CMP director Paul Howard at Read more about CMP topics...

Time to Trade in the 'Cadillac Tax' on Health Insurance Paul Howard, National Review Online, 09-14-15

Why I'm Not Worried About Drug Prices Yevgeniy Feyman,, 09-09-15

America's Health Care-Cost Slowdown Goes Kaput Paul Howard,, 08-22-15

How Will Scott Walker Pay For His Plan To Replace Obamacare? It's Largely Unclear Avik Roy,, 08-18-15

No, Donald Trump, Single-Payer Health Care Doesn't 'Work Incredibly Well' Avik Roy,, 08-07-15

The Informed Patient 2.0 Yevgeniy Feyman,, 08-04-15

Reform Obamacare By Returning Power And Money To The States Paul Howard, Yevgeniy Feyman, National Review Online, 07-30-15

The Next 50 Years For Medicare And Medicaid Yevgeniy Feyman, New York Times Room for Debate, 07-30-15

21st Century Cures Is Good Health (And Fiscal) Policy Paul Howard, Yevgeniy Feyman,, 07-09-15


Unlocking the Code of Health: Bridging the Gap Between Precision Medicine and FDA Regulation
By Peter Huber, Paul Howard
March 2015

Health Savings Accounts Under the Affordable Care Act: Challenges and Opportunities for Consumer-Directed Health Plans
By Paul Howard and Yevgeniy Feyman
October 2014

Transcending Obamacare: A Patient-Centered Plan for Near-Universal Coverage and Permanent Fiscal Solvency
by Avik Roy
August 2014

An FDA Report Card: Wide Variance in Performance Found Among Agency's Drug Review Divisions
by Joseph A. DiMasi, Christopher-Paul Milne, Alex Tabarrok
April 2014

A Decade of Success: How Competition Drives Savings in Medicare Part D
by Paul Howard and Yevgeniy Feyman
December 2013

Rhetoric and Reality—The Obamacare Evaluation Project: Access to Care and the Physician Shortage
by Paul Howard and Yevgeniy Feyman
June 2013


TheCure in the Code
Why Obama's Government Takeover of Health-Care Will Be a Disaster
Who Killed Health Care
The Cure: How Capitalism Can Save American Care

Paul Howard

Peter W. Huber

Avik Roy


Yevgeniy Feyman



Richard Epstein and Paul Howard discuss the findings from Richard’s new report, "The FDA's Misguided Regulation of Stem-Cell Procedures" and how administrative overreach is blocking medical innovation.


Yevgeny Feyman and co-authors John Kaplan and Daniel Gorlin discuss their recent report "Alternative Care Models Show Improved Healthcare Value."




For more information on the
Center for Medical Progress,
please contact Katherine Lazarski,



Medicare and Medicaid are the nation's two largest entitlement programs. They are also facing multi-trillion dollar deficits in coming decades as expenditures dwarf tax revenues. While some have advocated that the U.S. adopt a Canadian-style "single-payer" health care system to reign in costs, the Manhattan Institute recognizes that price controls and rationing will only exacerbate the health care challenges facing our nation, not solve them. Reforming these programs means opening Medicare and Medicaid to private insurance markets and putting consumers, not bureaucrats, in control of their own health care spending through health savings accounts and targeted vouchers. Empowered consumers make rational, cost-effective choices without dampening the market incentives driving health care innovation. Read more on this topic >>


Third-party payment plans allow some consumers to use services without ever paying the full cost of health care utilization, while others pay for benefits they don't need. The result is a system where health care costs spiral out of control and consumer choice is limited to "one-size-fits-all" medicine. The CMP wants to change this system by making it a true market: putting consumers in charge of their own routine health care spending; reserving insurance for truly catastrophic injuries; and creating a national market for health insurance that encourages customized insurance plans and pricing competition. Read more on this topic >>


The discovery of rare side effects from drugs like Vioxx and Celebrex has politicians and the media clamoring for larger, longer, and more expensive clinical trials by the Food and Drug Administration. But there is no evidence that reliance on additional "one-size-fits-all" clinical trials will make prescription drugs safer. Moreover, it will cost more lives due to slowed access to new medicines. The CMP's prescription for reform is more science, not more regulation. Science-driven FDA reform can help improve drug safety, streamline drug development and accelerate the adoption of personalized medicine. To achieve these goals, the Manhattan Institute has formed Project FDA, composed of leading experts that will develop a platform for FDA reform that will help the agency meet health care challenges in the 21st century using cutting-edge science and market-friendly policies. Read more on this topic >>


The U.S. is the world's leader in biopharmaceutical innovation, mainly because the U.S. does not impose price controls on prescription drugs. However, the rise of the internet has given individual U.S. consumers access to drugs in price controlled countries, leading to a growing demand that policymakers legalize importation on a national level. This policy would undermine medical innovation, while sending pharmaceutical investment and innovation now conducted in the U.S. to our rapidly developing competitors in China and India. The CMP is devoted to cataloguing the benefits of market driven medical innovation, both in economic and human terms, and in shifting the debate on drug importation to a question of free trade. After all, since the entire world benefits from the premium U.S. consumers pay for drug research and development, U.S. trade negotiators should encourage rich nations to help bear the full costs of drug development. Read more on this topic >>




The Manhattan Institute, a 501(c)(3), is a think tank whose mission is to develop and disseminate new ideas
that foster greater economic choice and individual responsibility.

Copyright © 2015 Manhattan Institute for Policy Research, Inc. All rights reserved.

52 Vanderbilt Avenue, New York, N.Y. 10017
phone (212) 599-7000 / fax (212) 599-3494